Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Regeneron Pharmaceuticals (REGN)

Regeneron Q4 revenue rises 3% to $3.9 billion; GAAP EPS falls 2% to $7.86

Mixed Impact 3 of 5 earnings Written later

Regeneron reported fourth quarter 2025 total revenues of $3.9 billion, up 3% from a year earlier, while fourth quarter GAAP earnings per diluted share fell 2% to $7.86. For full year 2025, revenues rose 1% to $14.3 billion and GAAP EPS rose 8% to $41.48, and the company also gave full year 2026 financial guidance.

Key points

  • Q4 2025 total revenues were $3,884 million, up 3% from $3,789 million in Q4 2024.
  • Q4 2025 GAAP EPS was $7.86 versus $8.06; non-GAAP EPS was $11.44 versus $12.07.
  • Full year 2025 GAAP EPS was $41.48 versus $38.34; full year non-GAAP EPS was $44.31 versus $45.62.
  • The company repurchased $3.5 billion of its stock in 2025 and declared a $0.94 per share dividend payable March 5, 2026.

The filing

CompanyRegeneron Pharmaceuticals (REGN)
Form8-K, current report
Filed with the SECJan 30, 2026, 6:51 AM ET
Accession number0000872589-26-000004

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.